These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144 [TBL] [Abstract][Full Text] [Related]
6. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470 [TBL] [Abstract][Full Text] [Related]
7. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotic activity and its relationship to in vitro anticoagulant effects. Gray E; Padilla A; Barrowcliffe TW Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358 [TBL] [Abstract][Full Text] [Related]
9. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Fareed J; Walenga JM; Racanelli A; Hoppensteadt D; Huan X; Messmore HL Haemostasis; 1988; 18 Suppl 3():33-47. PubMed ID: 2840373 [TBL] [Abstract][Full Text] [Related]
10. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan. Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402 [TBL] [Abstract][Full Text] [Related]
11. [Is there a difference between low-molecular-weight heparins?]. Eritsland J Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2802-3. PubMed ID: 16244685 [TBL] [Abstract][Full Text] [Related]
12. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [TBL] [Abstract][Full Text] [Related]
13. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy. Béguin S; Welzel D; Al Dieri R; Hemker HC Haemostasis; 1999; 29(2-3):170-8. PubMed ID: 10629396 [TBL] [Abstract][Full Text] [Related]
14. Heparin and low molecular weight heparin: background and pharmacology. Morris TA Clin Chest Med; 2003 Mar; 24(1):39-47. PubMed ID: 12685055 [TBL] [Abstract][Full Text] [Related]
15. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Poli M; Asperti M; Ruzzenenti P; Mandelli L; Campostrini N; Martini G; Di Somma M; Maccarinelli F; Girelli D; Naggi A; Arosio P Biochem Pharmacol; 2014 Dec; 92(3):467-75. PubMed ID: 25241290 [TBL] [Abstract][Full Text] [Related]
16. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats. Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564 [TBL] [Abstract][Full Text] [Related]
17. Rational design of low-molecular weight heparins with improved in vivo activity. Sundaram M; Qi Y; Shriver Z; Liu D; Zhao G; Venkataraman G; Langer R; Sasisekharan R Proc Natl Acad Sci U S A; 2003 Jan; 100(2):651-6. PubMed ID: 12525684 [TBL] [Abstract][Full Text] [Related]
18. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143 [TBL] [Abstract][Full Text] [Related]
19. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin. Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302 [TBL] [Abstract][Full Text] [Related]
20. New data on the pharmacology of heparin and low molecular weight heparins. Samama MM; Bara L; Gouin-Thibault I Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]